We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Download Mobile App





World’s First Phase 3 Clinical Trial of China’s COVID-19 Inactivated Vaccine Begins in UAE

By HospiMedica International staff writers
Posted on 20 Jul 2020
Print article
Image: World’s First Phase 3 Clinical Trial of China’s COVID-19 Inactivated Vaccine Begins in UAE) (Photo courtesy of AETOSWire)
Image: World’s First Phase 3 Clinical Trial of China’s COVID-19 Inactivated Vaccine Begins in UAE) (Photo courtesy of AETOSWire)
The first WHO enlisted global clinical Phase 3 trial of China’s inactivated vaccine to combat COVID-19 has begun in Abu Dhabi, UAE.

The inactivated COVID-19 vaccine has been developed by the Wuhan Institute of Biological Products under the China National Biotec Group (CNBG) affiliated to the China National Pharmaceutical Group Co., Ltd. (Sinopharm Beijing, China). The world's first inactivated COVID-19 vaccine produced antibodies in every participant in Phase 1/2 clinical trials. Sheikh Abdullah bin Mohammed Al Hamed, Chairman of the Department of Health, Abu Dhabi, was the first in the world to commence the trial of a Phase 3 inactivated vaccine for COVID-19. The UAE was selected to conduct the trials as the nation is home to over 200 nationalities, allowing for robust research across multiple ethnicities and increasing its feasibility for global application.

The trials are as a result of a cooperation partnership between G42 Healthcare and Sinopharm CNBG, the world’s sixth largest vaccine manufacturer. UAE Health Authorities have issued a permit for up to 15,000 volunteers to participate in the trials while G42 Healthcare and Abu Dhabi Health Services (SEHA) are working towards achieving a minimum of 5,000 participants for the trials being supervised by the Department of Health Abu Dhabi and SEHA following international guidelines stipulated by WHO and USFDA.

“Our participation in this trial enables us to make a major contribution in the global fight to combat the COVID-19 pandemic. We are proud to facilitate the testing process that if successful leads to the manufacture of a vaccine,” said Dr. Nawal Ahmed Alkaabi, Chairperson of the UAE National COVID-19 Clinical Management Committee.

“We are enormously proud to partner with Sinopharm CNBG in this groundbreaking phase III clinical trial. Using our AI solutions, super-computer, advanced diagnostics solutions for COVID-19, and G42 Healthcare will be responsible for running clinical operations for these trials,” said Ashish Koshy, CEO of G42 Healthcare.

“The UAE is a nation of innovation and tolerance, home to individuals from every part of the world and ethnic background. We will work closely with our partner G42 Healthcare, with the support of the Abu Dhabi health authorities to complete these clinical trials successfully and make this vaccine available to people in need worldwide,” added Jingjin Zhu, President, Biological products, Sinopharm CNBG.

Related Links:
China National Pharmaceutical Group Co., Ltd.

BMP Whole Blood Analyzer: GEM Premier ChemSTAT
Gold Supplier
ESR Analyzer
miniiSED™
New
Rapid Immunological FOB Test
Fecal Occult Blood Test
New
Albumin Urine Test
Micro-Albumin ELISA

Print article
Radcal

Channels

AI

view channel
Image: AI transforms smartwatch ECG signals into a diagnostic tool for heart failure (Photo courtesy of Pexels)

AI-Based Smartwatch Accurately Detects Heart Failure Using ECG Signals

People with a weak heart pump might not have symptoms, but this common form of heart disease affects about 2% of the population and 9% of people over 60. When the heart cannot pump enough oxygen-rich blood,... Read more

Critical Care

view channel
Image: The genetically engineered FcMBL protein can capture more than 100 different microbial species (Photo courtesy of Wyss Institute)

Rapid Pathogen Capture Technology Could Accelerate Diagnosis of Bloodstream Infections and Sepsis

Bloodstream infections (BSIs) with various microbial pathogens can rapidly escalate to life-threatening sepsis when the body is overwhelmed by the multiplying invaders and shuts down its organs’ functions.... Read more

Surgical Techniques

view channel
Image: CystoSmart image enhancement and AI diagnostic tool will enhance cancer detection (Photo courtesy of Claritas HealthTech)

AI Diagnostic Tool Improves Cancer Detection in Cystoscope Images of Bladder

Bladder cancer is the 10th commonest cancer worldwide and the 6th commonest cancer amongst men. It is known to have high recurrence rates and significant risks of disease progression. Early detection of... Read more

Patient Care

view channel
Image: Automated cleaning system allows endoscopes to be cleaned direct from clinic (Photo courtesy of Aston University)

World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance

Endoscopes are long, thin tubes with a light and camera at one end. Due to the sensitivity of the materials and electronics they cannot be sterilized in an autoclave (a machine that uses steam under pressure),... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Business

view channel
Image: The global multiparameter patient monitoring systems market is expected to surpass USD 15 billion by 2028 (Photo courtesy of Unsplash)

Global Multiparameter Patient Monitoring Systems Market Driven by Rising Chronic Illnesses

Multi-parameter patient monitoring equipment is used to assess the vital signs of patients who are suffering from a serious illness. These devices are meant to give the number of data sets on one screen... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.